המחאה החברתית לישראל-SATWORLD.ORG
האם אתה רוצה להגיב להודעה זו? אנא הירשם לפורום בכמה לחיצות או התחבר כדי להמשיך.
המחאה החברתית לישראל-SATWORLD.ORG

המחאה החברתית לישראל. מחזירים את המדינה לידי העם !

חיפוש
 
 

Display results as :
 


Rechercher חיפוש מתקדם

התחבר

שכחתי את סיסמתי



גולן טלקום החלה בהרשמה ל"גולן בוקס" - ממיר טלוויזיה, אינטרנט וטלפון

Tue Jun 16, 2015 11:45 pm על ידי יוחנן המדביר הלאומי

גולן טלקום החלה בהרשמה ל"גולן בוקס" - ממיר טלוויזיה, אינטרנט וטלפון

גולן טלקום פונה לטריפל: חברת הסלולר פתחה אתר להרשמה מוקדמת לקבלת מידע על חבילה הכוללת ממיר טלוויזיה, אינטרנט וטלפוניה. מדובר בצעד שיווקי שכן המחירים טרם …


[ Full reading ]

Comments: 2

שמוש בצלחת ישנה של יס

Fri Nov 05, 2010 8:03 pm על ידי davidh2

יש לי צלחת עם עינית של יס (אני מנותק מיס) שמחוברת לממיר. אני קולט טוב את הערוצים החופשיים בעיברית , המזרח התכון ועוד תחנת חדשות רוסית באנגלית.
האם ניתן בעזרת אותה עינית לקלוט לווין נוסף בעל תחנות חופשיות באנגלית?
אם כל …

[ Full reading ]

Comments: 38

פורום זה פתוח רק לחברי קהילת הלווין הישראלית בלבד

Sun May 22, 2011 3:07 pm על ידי satworld

פורום זה פתוח רק לחברי קהילת הלווין הישראלית בלבד
מי שלא חבר לא רואה את כל הפורום או לא יכול להכנס אליו
חובה רישום בפורום ומשלוח 10 הודעות בפורום
הקבלה לקהילה היא על תנאי .
כל עוד מכבדים את התקנון ותקנות הקהילה .
עם החברות …

[ Full reading ]

Comments: 2

ממיר המאפשר קליטת כל הערוצים הפרוצים כיום ללא שיתןף

Sat Jul 19, 2014 2:15 pm על ידי tomer_1968

איזה ממירים קיימים  התומכים בקליטת הערוצים הפרוצים כיום   האם קיוב קפה למשל תומך בכך תודה
צריך לקנות ממיר HD

Comments: 3

מבצע ההתקנות צלחת לווין יוצא לדרך עם עדיפות לחברי הקהילה

Wed Sep 09, 2009 10:40 am על ידי satworld

המבצע מיועד לחברי הקהילה
התקנת צלחות לווין לחברי הקהילה
המבצעת AME
בכל הארץ
טכנאים מטעם החברה עם אחריות של שנה
3שנים אחריות שנים לצלחות הלווין
שנה לדיסק
3.שנים אחריות שנים לכבלים



התקנת 2 צלחות עם 8 לווינים
צלחת מטר 1


[ Full reading ]

Comments: 2

TOPFEILD 7700-7070 פעם ראשונה בעולם בשיתוף תודה ל DAVA

Wed Jun 24, 2009 8:30 am על ידי tizinabi

פעם ראשונה בעולם הצלחנו להפעיל שיתוף על טופפילד 7700HD
7070HD
השיתוף שפועל הוא CAMD3
כולל HD
מנהל פרוייקט DVD מוריס ואושר
תודה ענקית ל DAVA שעשה ימים כלילות בכדי להפעיל אותו ולמדנו רבות מניסיונו
הרסנו ממיר HD אחד כזה במלך …

[ Full reading ]

Comments: 5

ערוצי הסקס בלווינים:

Tue Oct 06, 2009 7:53 am על ידי ROYALCONDOM

ערוצי הסקס בלווינים:


בתדר 11938 H -יש 4 ערוצי Redlight
בתדר 12092 H - יש 6 ערוצי SEX של חבילת Satisfaction

13E

בתדר 11411 H - יש ערוץ Dorcel האיכותי וכן 5 ערוצי Sex On
בתדר 11727 V - יש 5 ערוצי Satisfaction (נסרקים בשם S1...S5 )
בתדר 12207 H - יש 2 ערוצי Free X ו Free X2
בתדר 10853 H - …

[ Full reading ]

Comments: 8

תקנון פורום קהילת הלווין הישראלית

Wed Jan 28, 2009 12:34 pm על ידי satworld

תקנון פורום קהילת הלווין הישראלית.
גולש יקר,
אנו מודים לך על כי בחרת להיכנס לאתר ולפורום היחיד של קהילת הלווין הישראלית "SATWORLD.TK" ו/או לכל עמוד ו/או מדור שלו, בין אם הכניסה אליהם היא דרך שם מתחם (Domain Name) www.SATWORLD.TKובין אם …

[ Full reading ]

Comments: 7

maiai kohen

Sun Apr 03, 2022 1:15 am על ידי Anonymous

דרושים לעבודות קלדנות סקרים כתיבה 
תמלול פרטים בוואטצפ 0502322173

Comments: 0

RSS feeds

Yahoo! 
MSN 
AOL 
Netvibes 
Bloglines 



You are not connected. Please login or register

תרופה חדשה לחולי דמנציה ואלצהיימר: התרופה בדרך לאישור Aducanumab for Alzheimer’s

Go down  הודעה [עמוד 1 מתוך 1]

dima9000


SATWORLD VIP

התקווה החדשה לחולי אלצהיימר: הכל על התרופה שבדרך לאישור
חברת ביוג'ן הדהימה אתמול בהודעתה כי התרופה שפיתחה נגד אלצהיימר מוגשת לאישור מינהל המזון והתרופות האמריקני, בעקבות המחקרים שהראו כי התרופה מעכבת את התפתחות המחלה בשלבים המוקדמים שלה. איך היא עובדת, והאם אכן מדובר בפריצת דרך?
Aducanumab for Alzheimer’s


Biogen is planning to file for U.S. regulatory approval for its Alzheimer's treatment after fresh analysis of its clinical trial showed promise, the drugmaker said. CNBC's Meg Tirrell Reports.







The PRIME study of the immunotherapy agent aducanumab for Alzheimer’s disease made big news recently. An investigator in ongoing phase 3 trials of the agent sizes up PRIME and looks to what’s next.










Biogen Will Take Alzheimer's Therapy to FDA, Reviving HopeBiogen Inc. will ask U.S. drug regulators to approve the company’s experimental Alzheimer’s therapy, reviving the nearly abandoned treatment after a new analysis of data from two failed clinical trials showed promising 


 


תרופה חדשה לחולי דמנציה ואלצהיימר: התרופה בדרך לאישור Aducanumab for Alzheimer’s ALZHEIMER2תרופה חדשה לחולי דמנציה ואלצהיימר: התרופה בדרך לאישור Aducanumab for Alzheimer’s ALZHEIMER






Drug company Biogen Inc. intends to pursue regulatory approval from the Food and Drug Administration (FDA) for their experimental Alzheimer's drug, aducanumab, based on new analyses of data from their Phase 3 clinical trials. The study results showed reduced decline in people with mild cognitive impairment and mild dementia due to Alzheimer's disease who received the highest dose of the drug over a sufficient period of time.

Dr. Ronald Petersen, director of the Alzheimer's Disease Research Center at Mayo Clinic, says aducanumab targets the amyloid plaques in the brain that are believed to be an essential component of Alzheimer's disease.

More health and medical news on the Mayo Clinic News Network.
https://newsnetwork.mayoclinic.org/




















נערך לאחרונה על-ידי dima9000 בתאריך Thu Oct 24, 2019 4:03 am, סך-הכל נערך 4 פעמים

dima9000


SATWORLD VIP

https://www.cnbc.com/video/2019/10/22/biogen-fda-approval-alzheimers-drug-aducanumab.html
[size=30]Biogen to seek FDA approval for Alzheimer's drug Aducanumab[/size]

dima9000


SATWORLD VIP

https://www.neurologylive.com/clinical-focus/aducanumab-heads-to-the-fda-after-biogen-analysis-proves-positive-in-early-alzheimer-disease

Aducanumab Heads to the FDA After Biogen Analysis Proves Positive in Early Alzheimer Disease
After pulling the plug on trials in March 2019, Biogen has announced that an expanded analysis revealed significant positive results for aducanumab in patients with early Alzheimer disease. 

תרופה חדשה לחולי דמנציה ואלצהיימר: התרופה בדרך לאישור Aducanumab for Alzheimer’s Michel-Vounatsos

dima9000


SATWORLD VIP

[size=40]Biogen’s good news on aducanumab could ‘open the floodgates’ for Alzheimer’s drugs[/size]
https://www.statnews.com/2019/10/23/aducanumab-news-open-floodgates-alzheimers-drugs/



[size=33][size=33]That New Alzheimer’s Drug? Don’t Get Your Hopes Up Yet[/size][/size]
After declaring aducanumab a failure, the manufacturer now says the drug may help slow cognitive decline in certain patients. Some experts are skeptical.
https://www.nytimes.com/2019/10/22/health/alzheimers-dementia-aducanumab.html

תרופה חדשה לחולי דמנציה ואלצהיימר: התרופה בדרך לאישור Aducanumab for Alzheimer’s Merlin_163121928_46c138cf-3e91-4dd8-bd99-01ddaa60092f-superJumbo

A review of brain scans of patients with dementia at the Banner Alzheimer’s Institute in Phoenix. Biogen, a drug company, said on Tuesday that it would seek approval for a drug to treat early Alzheimer’s disease.CreditMatt York/Associated Press









[size=40]BIOGEN PLANS REGULATORY FILING FOR ADUCANUMAB IN ALZHEIMER’S DISEASE BASED ON NEW ANALYSIS OF LARGER DATASET FROM PHASE 3 STUDIES[/size]



https://investors.biogen.com/news-releases/news-release-details/biogen-plans-regulatory-filing-aducanumab-alzheimers-disease

dima9000


SATWORLD VIP

[size=42]Trick or Treat?’ Analysts react to Biogen’s aducanumab surprise[/size]


https://www.fiercebiotech.com/biotech/trick-or-treat-analysts-react-to-biogen-s-aducanumab-surprise

dima9000


SATWORLD VIP

[size=46]Aducanumab[/size]

[size=46]Aducanumab
HOME » ADUCANUMAB
[/size]


Aducanumab (BIIB037) was being developed by Biogen as a possible therapy for Alzheimer’s disease. However, in March 2019, an independent data monitoring committee determined there was insufficient evidence supporting the efficiency of aducanumab in treating the disease. As a result, all clinical trials testing the treatment have been halted.
The treatment was originally developed by Neurimmune, which, after entering a partnership with Biogen in 2007, had granted Biogen the license to further develop and commercialize aducanumab. Biogen had been collaborating with Eisai to advance the clinical studies of aducanumab since October 2017
https://alzheimersnewstoday.com/aducanumab/




[size=34]Neurimmune Welcomes Biogen's News on Clinical Benefit of Aducanumab

http://www.neurimmune.com/newsarticle/22102019-neurimmune-welcomes-biogens-news-on-clinical-benefit-of-aducanumab.html




[/size]

dima9000


SATWORLD VIP

https://www.medpagetoday.com/neurology/alzheimersdisease/82865
[size=32]Biogen Reverses Take on Aducanumab Trial Data[/size]

— Says reanalysis shows anti-amyloid drug is a winner for Alzheimer's disease

dima9000


SATWORLD VIP

Aducanumab

Aducanumab is a human monoclonal antibody that has been studied for the treatment of Alzheimer's disease (AD).[1] It was developed by Biogen Inc., which licensed the drug candidate from Neurimmune, its discoverer.[2] The antibody targets aggregated forms of β-amyloid found in the brains of people with Alzheimer’s disease, in the hopes of reducing its buildup.[3] Biogen halted development of the drug in March 2019 after preliminary data from two phase III trials suggested it would not meet the primary endpoint.[4][5][6] On 22 October 2019 Biogen announced that it would be re-starting the FDA approval process for aducanumab stating that new analysis of a larger dataset showed that the drug reduced clinical decline in patients with early Alzheimer's disease when given at higher doses.[7] The reanalysis of the data from the discontinued trial concluded that patients receiving a high dose had a 23% reduction in their rate of decline.[8][9]

Research


Interim results from the second Phase 1 study of the drug wer

[list=references]
[*] Cynthia Fox for Drug Discovery and Development (April 28, 2015). "The Story of Biogen's Alzheimer's Drug, Aducanumab Archived 2015-07-01 at the Wayback Machine".

[*]^ Rebecca Zacks for Xconomy (November 20, 2007). "Biogen Inks $380 Million Deal with Swiss Company".

[*]^ Toyn, Jeremy (2015). "What lessons can be learned from failed Alzheimer's disease trials?". Expert Rev. Clin. Pharmacol8 (3): 267–269. doi:10.1586/17512433.2015.1034690PMID 25860157.

[*]^ "Biogen Halts Promising Alzheimer's Drug Trials Due to Disappointing Results"Time. Retrieved 2019-03-21.

[*]^ https://www.cnbc.com/2019/03/21/biogen-shares-plunge-more-than-25percent-after-ending-trial-for-alzheimers-drug-aducanumab.html

[*]^ https://www.bostonglobe.com/business/2019/03/21/biogen-shares-plunge-after-alzheimer-drug-setback/0MzLJWlEgmo5nHSKWl8esO/story.html?p1=Article_Recommended_ReadMore_Pos1

[*]^ CNN, Jacqueline Howard and Jamie Gumbrecht. "Drugmaker to seek approval for Alzheimer's treatment"CNN. Retrieved 2019-10-23.

[*]^ Herper, Matthew (2019-10-22). "In shocking reversal, Biogen to submit Alzheimer's drug for approval"STAT. Retrieved 2019-10-22.

[*]^ "Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies"Biogen. Retrieved 2019-10-22.

[*]^ Matthew Herper for Forbes. March 20, 2015 Biogen Drug Could Inspire New Hope For Alzheimer's Treatments

[*]^ Jump up to:a b Sevigny J.; Chiao P.; Bussière T.; Weinreb P.H.; Williams L.; Maier M.; Dunstan R.; Salloway S.; Chen T.; Ling Y.; O'Gorman J.; Qian F.; Arastu M.; Li M.; Chollate S.; Brennan M.S.; Quintero-Monzon O.; Scannevin R.H.; Arnold H.M.; Engber T.; Rhodes K.; Ferrero J.; Hang Y.; Mikulskis A.; Grimm J.; Hock C.; Nitsch R.M.; Sandrock A. (1 September 2016). "The antibody aducanumab reduces Aβ plaques in Alzheimer's disease". Nature537(7618): 50–56. doi:10.1038/nature19323PMID 27582220.

[*]^ Li, Yun (21 March 2019). "Biogen shares plunge nearly 30% after ending trial for Alzheimer's drug Aducanumab". CNBC.

[*]^ "First drug to slow Alzheimer's may be available soon". BBC News. 22 October 2019. Retrieved 22 October 2019.

[/list]

e reported in March 2015.[1][10]

A phase 1b study was published in August 2016, based on one year of "monthly intravenous infusions" of aducanumab, with brain scans to measure amyloid plaques.[11] Phase 3 clinical trials were ongoing in September 2016,[11] but were canceled in March 2019 after "an independent group's analysis show[ed] that the trials were unlikely to 'meet their primary endpoint.'"[12]

Despite this, in October 2019 the company announced their intention to seek regulatory approval, following a reanalysis of the data

dima9000


SATWORLD VIP

[size=39]Biogen Halts Promising Alzheimer's Drug Trials Due to Disappointing Results[/size]
https://time.com/5555868/biogen-aducanumab-trials/


Pharmaceutical company Biogen is halting two global phase-three trials testing the once-promising Alzheimer’s drug aducanumab, delivering a late-stage blow to researchers searching for therapies for the incurable degenerative disease.
“This disappointing news confirms the complexity of treating Alzheimer’s disease and the need to further advance knowledge in neuroscience,” Biogen CEO Michel Vounatsos said in a statement Thursday. “We are incredibly grateful to all the Alzheimer’s disease patients, their families and the investigators who participated in the trials and contributed greatly to this research.”
Biogen and its Japanese partner Eisai decided to end the aducanumab trials after an independent data-monitoring committee determined that the drug was unlikely to provide benefit to Alzheimer’s patients compared to a placebo, the company said in its statement. The committee did not find safety issues associated with the drug.
Aducanumab was meant to slow the rate of cognitive decline and functional impairment in people with mild Alzheimer’s disease by clearing amyloid from the brain. Amyloid protein is thought to contribute to Alzheimer’s-related decline by forming sticky plaques in the brain, potentially compromising nerve cells and leading to dementia and memory loss. The trial’s failure, however, calls that amyloid hypothesis — and potential treatment path — into question.
It’s also yet another failure in the search for a drug that can fight Alzheimer’s disease, which has been riddled with bad news in recent years. In 2018, pharmaceutical companies including Eli LillyAstraZenecaPfizer and Merck halted research or development into possible Alzheimer’s and dementia therapies due to disappointing results.
Jamie Ducharme

dima9000


SATWORLD VIP

תרופה חדשה לחולי דמנציה ואלצהיימר: התרופה בדרך לאישור Aducanumab for Alzheimer’s Aducanumab%20Overview

[size=30]Aducanumab Overview

[/size]

Introduction of Aducanumab

Aducanumab, also known as BIIB037, is a human IgG1κ monoclonal antibody targeting a conformational epitope found on β-amyloid (Aβ) and has been used in trials studying the treatment of Alzheimer's disease (AD). It is derived from a de‑identified library of B cells collected from healthy elderly subjects with no signs of cognitive impairment, and cognitively impaired elderly subjects with unusually slow cognitive decline, and is being developed by Biogen Inc., which licensed the drug candidate from Neurimmune, its discoverer. The phase 3 clinical trials are ongoing.

Mechanism of Action of Aducanumab

The precise mechanism by which aducanumab exerts its therapeutic effects in AD is unknown, but is presumed to involve targeting aggregated forms of Aβ, including soluble oligomers and insoluble fibrils deposited into the amyloid plaque in the brain of AD patients. According to the results of a phase Ib study published in August 2016, aducanumab is shown to enter the brain of transgenic mouse model of AD, bind parenchymal Aβ, and reduce soluble and insoluble Aβ in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner.
https://www.creativebiolabs.net/aducanumab-overview.htm

dima9000


SATWORLD VIP

https://www.nature.com/articles/nature19323

Article | Published: 31 August 2016
[size=39]The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease[/size]

dima9000


SATWORLD VIP

http://www.neurimmune.com/newsarticle/
Neurimmune is a biopharmaceutical company translating B-cell derived genetic information of human immune repertoires into antibody therapeutics.
Neurimmune discovered aducanumab together with a team of researchers at the University of Zurich and licensed it to Biogen. Neurimmune collaborates on aducanumab with Biogen who co-develops it with Eisai.
Aducanumab is a human monoclonal antibody removing beta amyloid in brains of patients with Alzheimer’s disease. Based on large Phase 3 study results showing clinical benefit, Biogen plans regulatory filing for aducanumab in Alzheimer’s disease.
Neurimmune’s pipeline comprises drug candidates for diseases of the central nervous system and related protein aggregation diseases. With its Reverse Translational Medicine technology platform, Neurimmune is able to discover human antibodies against virtually any pharmacological target structure in the human body.

dima9000


SATWORLD VIP

תרופה חדשה לחולי דמנציה ואלצהיימר: התרופה בדרך לאישור Aducanumab for Alzheimer’s Alzheimer-lesionsתרופה חדשה לחולי דמנציה ואלצהיימר: התרופה בדרך לאישור Aducanumab for Alzheimer’s Fonctionnement-aducanumabתרופה חדשה לחולי דמנציה ואלצהיימר: התרופה בדרך לאישור Aducanumab for Alzheimer’s Resultats-aducanumab
https://www.en24.news/2019/10/revolutionary-drug-for-alzheimers-disease-resurfaces.html
[size=41]revolutionary drug for Alzheimer's disease resurfaces[/size]
[size=41]In March 2019, the biopharmaceutical company Biogen stopped the clinical trials for a new molecule used in the treatment of Alzheimer's disease: aducanumab. This drug, described as revolutionary at the time of its presentation, directly targets the amyloid deposits responsible – in part – for the disease. It represented a real hope for the millions of patients around the world, and stopping its development, for obvious reasons of inefficiency, was a shock for all patients. However, by re-analyzing the data from the two clinical trials, Biogen's researchers found that aducanumab slowed the progression of the disease at a high dose. A hopeful turnaround that should bring the drug back to trial.[/size]
[size=41]תרופה חדשה לחולי דמנציה ואלצהיימר: התרופה בדרך לאישור Aducanumab for Alzheimer’s Aducanumab-alzheimer[/size]

dima9000


SATWORLD VIP

Paper Alert: Aducanumab Phase 1b Study Published
https://www.alzforum.org/news/research-news/paper-alert-aducanumab-phase-1b-study-published
Scientists at Biogen have formally published the results of a clinical trial that dazzled the Alzheimer's disease field last year: Aducanumab, a monoclonal antibody against Aβ, wiped out a hefty proportion of plaques in the brains of people with AD. The findings, reported in the August 31 Nature, also hint at a functional benefit. On two tests of cognition, people on the drug declined more slowly and in a roughly dose-dependent manner. Incidences of brain-imaging abnormalities called ARIA-E, indicative of fluid build-up in the brain, also cropped up dose-dependently, but these abnormalities were transient. Alfred Sandrock of Biogen in Cambridge, Massachusetts, and Roger Nitsch of Neurimmune in Zurich co-led the trial. Some researchers lamented the overinterpretation of underpowered cognitive data, but applauded the drug’s apparent plaque-fighting powers. The field now awaits the results of two ongoing Phase 3 trials, powered to conclusively tease out any clinical benefits.  

dima9000


SATWORLD VIP

תרופה חדשה לחולי דמנציה ואלצהיימר: התרופה בדרך לאישור Aducanumab for Alzheimer’s Alzheimers_amyloid_antibody_nature19323-f1_header
[size=32]New Alzheimer’s drug clears abnormal protein clogs in small, promising trial[/size]
https://www.pbs.org/newshour/science/new-alzheimers-drug-clears-amyloid-protein-clogs-small-promising-trial


[size=30]Aducanumab is an antibody, a natural substance the body produces to fight disease.תרופה חדשה לחולי דמנציה ואלצהיימר: התרופה בדרך לאישור Aducanumab for Alzheimer’s Nature19323-f1-769x1024[/size]

dima9000


SATWORLD VIP

http://www.brainimmune.com/aducanumab-shows-promise-impressive-effects-reducing-alzheimers-amyloid-%CE%B2-plaques/


תרופה חדשה לחולי דמנציה ואלצהיימר: התרופה בדרך לאישור Aducanumab for Alzheimer’s Merlin_163121928_46c138cf-3e91-4dd8-bd99-01ddaa60092f-superJumbo

Aducanumab Shows Promise and Impressive Effects in Reducing Alzheimer’s Amyloid-β Plaques

2016


תרופה חדשה לחולי דמנציה ואלצהיימר: התרופה בדרך לאישור Aducanumab for Alzheimer’s Timthumb.php?src=http%3A%2F%2Fwww.brainimmune.com%2Fwp-content%2Fuploads%2F2016%2F10%2Famyloid-hypothesis-aducanumab

[size=33][size=33]That New Alzheimer’s Drug? Don’t Get Your Hopes Up Yet[/size][/size]
After declaring aducanumab a failure, the manufacturer now says the drug may help slow cognitive decline in certain patients. Some experts are skeptical.
https://www.nytimes.com/2019/10/22/health/alzheimers-dementia-aducanumab.html

dima9000


SATWORLD VIP

dima9000


SATWORLD VIP

dima9000


SATWORLD VIP

[size=39]The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease[/size]
https://www.nature.com/articles/nature19323?platform=hootsuite

dima9000


SATWORLD VIP

[size=35]We're on the brink of the first new treatment for Alzheimer's in almost two decades. Here's what you need to know.[/size]
https://www.businessinsider.com/biogen-plans-to-file-alzheimers-drug-aducanumab-for-approval-2019-10

dima9000


SATWORLD VIP


  • An experimental treatment for Alzheimer's disease that was declared a failure in March has been brought back to life.

  • Biotech giant Biogen and its partner Eisai plan to seek approval for the Alzheimer's treatment, aducanumab, from the US Food and Drug Administration in 2020. 

  • In March, the drugmakers had stopped most of its research efforts into aducanumab after findings from two trials showed that the drug wasn't showing signs that it was working.

  • On Tuesday, Biogen said a new analysis of a larger dataset showed that the drug was "pharmacologically and clinically active" in trial participants who have Alzheimer's.


https://www.businessinsider.com/biogen-plans-to-file-alzheimers-drug-aducanumab-for-approval-2019-10

dima9000


SATWORLD VIP

US firm Biogen is hoping for approval to bring about a treatment that could slow the onset of Alzheimer’s disease.
http://www.pharmafile.com/news/531800/biogen-aiming-aducanumab-slow-alzheimer-s-progression

dima9000


SATWORLD VIP

[size=39]Biogen Alzheimer’s Drug Could Alter ‘Concept of Senior Living’[/size]
https://moneyandmarkets.com/biogen-alzheimers-drug-aducanumab/

dima9000


SATWORLD VIP


[size=45]Explained: Can ‘aducanumab’ treat Alzheimer’s disease? [/size]

A new analysis called “EMERGE” led by Biogen in consultation with the FDA shows that administration of the drug may be able to reduce clinical decline in patients in the early stages of Alzheimer’s disease.


https://moneyandmarkets.com/biogen-alzheimers-drug-aducanumab/


https://news.joindementiaresearch.nihr.ac.uk/aducanumab-positive-results-alzheimer/
Positive results from Alzheimer’s drug in Phase 1 clinical trial extension
The pharmaceutical company Biogen has today announced the results of an extended phase 1b clinical trial of the potential Alzheimer’s disease drug, aducanumab. Results from the extended early-stage trial were announced today at Clinical Trials in Alzheimer’s Disease (CTAD) conference in Boston.
https://news.joindementiaresearch.nihr.ac.uk/

חזרה למעלה  הודעה [עמוד 1 מתוך 1]

Permissions in this forum:
אתה לא יכול להגיב לנושאים בפורום זה